BOLD (Boundless Bio) ROE % Adjusted to Book Value : -81.62% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio ROE % Adjusted to Book Value?

Boundless Bio's ROE % for the quarter that ended in Sep. 2024 was -38.36%. Boundless Bio's PB Ratio for the quarter that ended in Sep. 2024 was 0.47. Boundless Bio's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -81.62%.

Boundless Bio ROE % Adjusted to Book Value Historical Data

The historical data trend for Boundless Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio ROE % Adjusted to Book Value Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Boundless Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	-	-	-743.35	-81.62

Competitive Comparison of Boundless Bio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Boundless Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Boundless Bio's ROE % Adjusted to Book Value falls into.

Boundless Bio ROE % Adjusted to Book Value Calculation

Boundless Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Boundless Bio's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-38.36%	/	0.47
	=	-81.62%

Boundless Bio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Boundless Bio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.